Company News: Pfizer

Share this article:

A study conducted by researchers at the University of Washington and published in medical journal The Lancet has found that a popular injectable contraceptive in Africa doubles the risk of women becoming infected with H.I.V. Nearly 4,000 couples who use the injectable were studied, hailing from countries scattered around Africa—Zambia, South Africa and Uganda, to name a few—and it was found that for women who are already H.I.V.-positive, their male partners were twice as likely to become infected than if their partner used no contraception at all. The branded version of the drug is Depo-Provera, manufactured by Pfizer, and reps for the pharma have yet to comment on the study.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.